期刊： JOURNAL OF IMMUNOTHERAPY, 2021; 44 (4)
Our previous research has shown that monocytic leukemia-associated antigen-34 (MLAA-34) was a novel antiapoptotic molecule with unique expression in a......
期刊： JOURNAL OF IMMUNOTHERAPY, 2021; 44 (6)
Premelanosome protein (PMEL) is crucial for the formation of melanosomal fibrils through the transition from stage I to stage II melanosomes. It was u......
期刊： JOURNAL OF IMMUNOTHERAPY, 2021; 44 (3)
Cancer therapies benefit from accelerated development of biotechnology, and many immunotherapeutic strategies spring up including vaccines, the immune......
期刊： JOURNAL OF IMMUNOTHERAPY, 2021; 44 (2)
Antibiotic (ATB) use seems to negatively affect the outcomes of immune checkpoint inhibitors (ICIs). The aim of this review is to clarify whether ATB ......
期刊： JOURNAL OF IMMUNOTHERAPY, 2021; 44 (1)
Colorectal cancer (CRC) is the third most common malignancy worldwide. The novel immune checkpoint V-domain Ig suppressor of T-cell activation (VISTA)......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (2)
T-cell immunoglobulin and mucin domain-3 (Tim-3) has been suggested to be a critical immune checkpoint target for cancer immunotherapy. However, limit......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (4)
Immunotherapy has exhibited promising but controversial results in gastric cancer; determining criteria for choosing the appropriate target population......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (5)
Paraneoplastic neurological syndromes (PNSs) are uncommon complications of immune-checkpoint inhibitor (ICI) therapy. This article reports a case of p......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (5)
As new members of the CD28/B7 costimulatory superfamily, PD-1 (programmed cell death 1) and its ligand PD-L1 (programmed cell death ligand 1) mediate ......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (9)
The authors conducted a multicenter retrospective study on the outcome of programmed death-ligand 1 tumor proportion score >= 50% advanced non-smal......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (9)
Tumor-specific Tc9 cells exhibit an excellent antitumor potential in tumor immunotherapy. Identification of factors that contribute to Tc9-cell differ......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (1)
Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates impressive efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (1)
Treatment with chimeric antigen receptor-modified T cell (CAR-T) has demonstrated promising therapeutic efficacy in hematologic malignancies. However,......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (6)
The aim of this study is to investigate the association between tumor mutation burden (TMB) and survival in non-small cell lung cancer (NSCLC) patient......
期刊： JOURNAL OF IMMUNOTHERAPY, 2020; 43 (6)
B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein expressed on malignant plasma cells of patients with multiple myeloma (MM),......
